Medtronic receives FDA approval for PRESTIGE cervical disc system Medtronic announced that it has received approval from the FDA to market the PRESTIGE LP Cervical Disc System for the treatment of single-level cervical disc disease. The PRESTIGE LP Cervical Disc is the third clinically proven artificial cervical disc in the Medtronic portfolio.
On The Fly: Analyst Upgrade Summary Today's noteworthy upgrades include: Actuant (ATU) upgraded to Neutral from Underweight at JPMorgan... Air Products (APD) upgraded to Buy from Neutral at Goldman... BRF S.A. (BRFS) upgraded to Buy from Neutral at Citi... China Lodging (HTHT) upgraded to Buy from Neutral at Goldman... Columbia Pipeline Group (CPGX) upgraded to Buy from Hold at Jefferies... Edgewell Personal Care (EPC) upgraded to Buy from Neutral at BofA/Merrill... Encore Capital (ECPG) upgraded to Buy from Neutral at Citi... Franco-Nevada (FNV) upgraded to Action List Buy from Buy at TD Securities... Genesco (GCO) upgraded to Strong Buy from Buy at CL King... Helmerich & Payne (HP) upgraded to Outperform at Scotia Howard Weil... Infinera (INFN) upgraded to Buy from Hold at Needham... Lufthansa (DLAKY) upgraded to Sector Perform from Underperform at RBC Capital... Medtronic (MDT) upgraded to Buy from Hold at Evercore ISI... Morgan Stanley (MS) upgraded to Outperform from Market Perform at JMP Securities... Navient (NAVI) upgraded to Buy from Neutral at Goldman... Nike (NKE) upgraded to Buy from Neutral at DA Davidson... Qualys (QLYS) upgraded to Outperform from Neutral at Credit Suisse... Standard Chartered (SCBFF) upgraded to Buy from Neutral at Goldman... Summit Materials (SUM) upgraded to Buy from Neutral at BofA/Merrill... Tahoe Resources (TAHO) upgraded to Outperformer from Sector Performer at CIBC... Tilly's (TLYS) upgraded to Buy from Neutral at B. Riley... Verifone (PAY) upgraded to Strong Buy from Outperform at Raymond James... Yum! Brands (YUM) upgraded to Neutral from Underperform at Credit Suisse.
Medtronic upgraded to Buy from Hold at Evercore ISI Evercore ISI upgraded Medtronic to Buy and increased its price target to $80. Analyst Vijay Kumar continues to view Medtronic as a compelling value given high free-cash-flow yield, low valuation, and attractive dividend yield. Kumar views Medtronic as a "must own" core holding and is "pounding the table" on shares.